INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) has decided to halt a Phase 2b obesity study, citing strategic business considerations, according to ClinicalTrials.gov.
The study was designed to evaluate the efficacy and safety of bimagrumab, tirzepatide, and their combination in reducing body weight in adults with obesity or overweight and type 2 diabetes.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
